Research On Expression Of Somatostatin Receptor2 And Somatostatin Receptor5 In Pancreatic Carcinoma

On the clinic the patients of pancreatic carcinoma usually use the SSA such as Octreotide , mostly aim at making use of its mainfold circadian activeness to ease the peristalysises of stomach and intestines and decrease the secretion of acid , especially to restrain pancreatic exocrine function , so that to speed the suture cicatrizes and avoid the sutural cleft and mainfold pathology reactions occuring after the operation .To exert the function mostly depends on the various approaches of signal conduction mediated after its combining with the SSR . But going by the discovering of the anti-tumor function of the SS , whether the SS and SSR can become the new breaching point turn to the focus people paying attention . Though SSA such as Octreotide is proved to be able to prevent the Pancreatic carcinoma from growing in many circumstances such as in vitro and in many experiments , lots of clinic experiments'results didn't come to perfect . A majority of scholars consider that this relates to the expression of SSR .Objective Apply SP Method in Immunohistochemistry , check the expression of SSR2,SSR5 in Pancreatic carcinoma suffer from the molecular albumenous level , and analyse contacting with the clinic information , so to provide that SSA cure Pancreatic carcinoma with theoretic gist .Methods Collect the cancerous tissues of the patients who were diagnosed as Pancreatic carcinoma after operation from December,1997 to May,2005 of our hospital and the pancreatic tissues of the patients who were diagnosed that their pancreas hadn't been invaded by the cancer from...